Related Experiment Videos
Identification of Fas (APO-1/CD95) and p53 gene mutations in non-small cell lung cancer
L Boldrini1, P Faviana, S Gisfredi
1Department of Oncology, Transplants and Advanced Technologies in Medicine, Pisa, Italy.
Abstract:
Fas (APO-1/CD95) is a broadly expressed death receptor involved in a series of physiological and pathological apoptotic processes. One of the possible mechanisms for resistance to apoptosis signaling in the immune system as well as in the pathogenesis of non-lymphoid malignancies is the presence of Fas mutations within the entire gene. We investigated, in 79 non-small cell lung cancer (NSCLC) samples, the promoter and the entire coding region of the Fas gene by polymerase chain reaction, single strand conformation polymorphism and DNA sequencing in order to detect putative alterations. Sixteen of 79 tumor samples (20.2%) were found to have Fas alterations, either in promoter or exon region. Since the loss of Fas apoptotic function might be linked to p53 alterations, which are often involved in the development of NSCLC, we analyzed p53 status in 40 of the 79 NSCLC samples. p53 mutations were found to be more frequently present than Fas gene alterations (25 out of 40 cases, 62.5%). These data increase the knowledge regarding mutations of apoptosis-genes involved in the pathogenesis of NSCLC, and give benefits for the clinical management of this type of tumor.
Insights
Mutations in the Fas gene, a key apoptosis regulator, were found in 20.2% of non-small cell lung cancer (NSCLC) samples. p53 mutations were more common, suggesting complex roles in NSCLC pathogenesis.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Fas (APO-1/CD95) is a death receptor crucial for apoptosis.
- Fas mutations can lead to apoptosis resistance and contribute to non-lymphoid malignancies.
- Non-small cell lung cancer (NSCLC) pathogenesis involves apoptosis dysregulation.
Purpose of the Study:
- To investigate alterations in the Fas gene promoter and coding regions in NSCLC.
- To determine the frequency of Fas gene mutations in NSCLC.
- To explore the relationship between Fas and p53 alterations in NSCLC.
Main Methods:
- Polymerase chain reaction (PCR) was used to amplify Fas gene regions.
- Single-strand conformation polymorphism (SSCP) and DNA sequencing identified mutations.
- p53 mutation status was analyzed in a subset of NSCLC samples.
Main Results:
- Fas alterations were detected in 16 out of 79 (20.2%) NSCLC samples.
- Alterations occurred in either the promoter or exon regions of the Fas gene.
- p53 mutations were found in 62.5% (25/40) of analyzed NSCLC cases, exceeding Fas mutation frequency.
Conclusions:
- Fas gene mutations are present in a significant subset of NSCLC.
- The high prevalence of p53 mutations suggests a more prominent role in NSCLC development compared to Fas mutations.
- Understanding these apoptosis-gene mutations aids in NSCLC clinical management.